CA2555911C - Compositions d'adjuvant contenant le lipide a monophosphoryle 3-o-deacetyle - Google Patents

Compositions d'adjuvant contenant le lipide a monophosphoryle 3-o-deacetyle Download PDF

Info

Publication number: CA2555911C
Authority: CA; Canada
Prior art keywords: mpl; rgd2t; hbsag; vaccine; formulation
Prior art date: 1993-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002555911A

Other languages

English (en)

Other versions

CA2555911A1 (fr

Inventor

Pierre Hauser

Pierre Voet

Moncef Slaoui

Nathalie Marie-Josephe Garcon-Johnson

Pierre Desmons

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

SmithKline Beecham Biologicals SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-23

Filing date

1994-03-14

Publication date

2009-09-08

1993-03-23 Priority claimed from GB939306029A external-priority patent/GB9306029D0/en

1994-02-23 Priority claimed from GB9403417A external-priority patent/GB9403417D0/en

1994-03-14 Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA

1994-03-14 Priority claimed from CA002157376A external-priority patent/CA2157376C/fr

1994-09-29 Publication of CA2555911A1 publication Critical patent/CA2555911A1/fr

2009-09-08 Application granted granted Critical

2009-09-08 Publication of CA2555911C publication Critical patent/CA2555911C/fr

2014-03-14 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229940035032 monophosphoryl lipid a Drugs 0.000 title claims abstract description 222
239000000203 mixture Substances 0.000 title claims abstract description 91
239000002671 adjuvant Substances 0.000 title claims abstract description 16
239000000725 suspension Substances 0.000 claims abstract description 11
239000012528 membrane Substances 0.000 claims abstract description 5
238000011146 sterile filtration Methods 0.000 claims abstract description 4
239000002245 particle Substances 0.000 claims description 59
238000000034 method Methods 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
239000008215 water for injection Substances 0.000 claims description 7
229960001438 immunostimulant agent Drugs 0.000 claims description 5
239000003022 immunostimulating agent Substances 0.000 claims description 5
230000003308 immunostimulating effect Effects 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
238000002604 ultrasonography Methods 0.000 claims description 4
239000002033 PVDF binder Substances 0.000 claims description 3
229920002981 polyvinylidene fluoride Polymers 0.000 claims description 3
239000003814 drug Substances 0.000 claims 1
238000005086 pumping Methods 0.000 claims 1
230000036512 infertility Effects 0.000 abstract description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 93
229910021502 aluminium hydroxide Inorganic materials 0.000 description 91
238000009472 formulation Methods 0.000 description 78
229910001679 gibbsite Inorganic materials 0.000 description 51
229960005486 vaccine Drugs 0.000 description 49
239000000427 antigen Substances 0.000 description 38
102000036639 antigens Human genes 0.000 description 38
108091007433 antigens Proteins 0.000 description 38
238000002474 experimental method Methods 0.000 description 30
208000015181 infectious disease Diseases 0.000 description 29
230000000306 recurrent effect Effects 0.000 description 28
230000004044 response Effects 0.000 description 26
210000004027 cell Anatomy 0.000 description 25
241000699670 Mus sp. Species 0.000 description 23
230000000694 effects Effects 0.000 description 23
201000010099 disease Diseases 0.000 description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
238000002649 immunization Methods 0.000 description 19
241000700198 Cavia Species 0.000 description 18
230000006698 induction Effects 0.000 description 18
238000002255 vaccination Methods 0.000 description 18
238000002965 ELISA Methods 0.000 description 17
241001465754 Metazoa Species 0.000 description 17
208000027930 type IV hypersensitivity disease Diseases 0.000 description 17
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 16
230000003472 neutralizing effect Effects 0.000 description 16
239000000243 solution Substances 0.000 description 16
230000005951 type IV hypersensitivity Effects 0.000 description 16
230000003053 immunization Effects 0.000 description 14
230000005847 immunogenicity Effects 0.000 description 14
230000003902 lesion Effects 0.000 description 14
230000028327 secretion Effects 0.000 description 14
230000001225 therapeutic effect Effects 0.000 description 13
241000709721 Hepatovirus A Species 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
241000282693 Cercopithecidae Species 0.000 description 10
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
208000002672 hepatitis B Diseases 0.000 description 10
239000000600 sorbitol Substances 0.000 description 10
241000288906 Primates Species 0.000 description 9
230000000069 prophylactic effect Effects 0.000 description 9
230000024932 T cell mediated immunity Effects 0.000 description 8
230000001681 protective effect Effects 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
150000001413 amino acids Chemical group 0.000 description 7
208000005252 hepatitis A Diseases 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
238000000527 sonication Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000011282 treatment Methods 0.000 description 7
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 6
206010015150 Erythema Diseases 0.000 description 6
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 6
108090000978 Interleukin-4 Proteins 0.000 description 6
108700006640 OspA Proteins 0.000 description 6
241000700605 Viruses Species 0.000 description 6
230000005875 antibody response Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
230000004727 humoral immunity Effects 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
230000004224 protection Effects 0.000 description 6
229940124914 Havrix Drugs 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000001914 filtration Methods 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
238000011084 recovery Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
241000282552 Chlorocebus aethiops Species 0.000 description 4
241000700721 Hepatitis B virus Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
239000013020 final formulation Substances 0.000 description 4
208000006454 hepatitis Diseases 0.000 description 4
231100000283 hepatitis Toxicity 0.000 description 4
229940124736 hepatitis-B vaccine Drugs 0.000 description 4
229940029583 inactivated polio vaccine Drugs 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000000240 adjuvant effect Effects 0.000 description 3
238000013019 agitation Methods 0.000 description 3
239000004411 aluminium Substances 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
230000002238 attenuated effect Effects 0.000 description 3
229940001442 combination vaccine Drugs 0.000 description 3
238000002296 dynamic light scattering Methods 0.000 description 3
231100000321 erythema Toxicity 0.000 description 3
238000011554 guinea pig model Methods 0.000 description 3
229960002520 hepatitis vaccine Drugs 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000000405 serological effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
206010040882 skin lesion Diseases 0.000 description 3
231100000444 skin lesion Toxicity 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003860 storage Methods 0.000 description 3
102100031673 Corneodesmosin Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
201000005702 Pertussis Diseases 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
206010043376 Tetanus Diseases 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
206010013023 diphtheria Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
230000035800 maturation Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229940021747 therapeutic vaccine Drugs 0.000 description 2
239000010936 titanium Substances 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000589968 Borrelia Species 0.000 description 1
241000448699 Borrelia burgdorferi ZS7 Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
206010061819 Disease recurrence Diseases 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
229940124884 Engerix-B Drugs 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
241001497337 Euscorpius gamma Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
208000022555 Genital disease Diseases 0.000 description 1
206010048461 Genital infection Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000701024 Human betaherpesvirus 5 Species 0.000 description 1
101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
241001092142 Molina Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000224016 Plasmodium Species 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
101710137302 Surface antigen S Proteins 0.000 description 1
102100021696 Syncytin-1 Human genes 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
241000223996 Toxoplasma Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
-1 Tween 80 Chemical compound 0.000 description 1
206010048937 Vaginal lesion Diseases 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
244000037640 animal pathogen Species 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000011246 composite particle Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007689 endotoxicity Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
201000010284 hepatitis E Diseases 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
229940124724 hepatitis-A vaccine Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229940042470 lyme disease vaccine Drugs 0.000 description 1
101710130522 mRNA export factor Proteins 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
229940031348 multivalent vaccine Drugs 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000007501 viral attachment Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1

Classifications

- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Anti-Oxidant Or Stabilizer Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002555911A 1993-03-23 1994-03-14 Compositions d'adjuvant contenant le lipide a monophosphoryle 3-o-deacetyle Expired - Lifetime CA2555911C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB9306029.1		1993-03-23
GB939306029A GB9306029D0 (en)	1993-03-23	1993-03-23	Vaccine compositions
GB9403417A GB9403417D0 (en)	1994-02-23	1994-02-23	Vaccine compositions
GB9403417.0		1994-02-23
CA002157376A CA2157376C (fr)	1993-03-23	1994-03-14	Compositions de vaccin contenant du derive 3-o-desacetyle du lipide a monophosphoryle

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002157376A Division CA2157376C (fr)	1993-03-23	1994-03-14	Compositions de vaccin contenant du derive 3-o-desacetyle du lipide a monophosphoryle

Publications (2)

Publication Number	Publication Date
CA2555911A1 CA2555911A1 (fr)	1994-09-29
CA2555911C true CA2555911C (fr)	2009-09-08

Family

ID=37310259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002555911A Expired - Lifetime CA2555911C (fr)	1993-03-23	1994-03-14	Compositions d'adjuvant contenant le lipide a monophosphoryle 3-o-deacetyle

Country Status (1)

Country	Link
CA (1)	CA2555911C (fr)

1994
- 1994-03-14 CA CA002555911A patent/CA2555911C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2555911A1 (fr)	1994-09-29

Legal Events

Date	Code	Title	Description
2006-08-11	EEER	Examination request
2014-05-18	MKEX	Expiry	Effective date: 20140314

Publication	Publication Date	Title
EP0689454B2 (fr)	2005-02-23	Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
JP3881015B2 (ja)	2007-02-14	Ｂ型肝炎ワクチン
RU2121849C1 (ru)	1998-11-20	Вакцинная композиция против гепатита, способ профилактики гепатита
CA2555911C (fr)	2009-09-08	Compositions d'adjuvant contenant le lipide a monophosphoryle 3-o-deacetyle
AU705739B2 (en)	1999-06-03	A method of preparing vaccine compositions containing 3-0-deacylated monophosphoryl lipid A
CA2157376C (fr)	2006-10-31	Compositions de vaccin contenant du derive 3-o-desacetyle du lipide a monophosphoryle
US20020192224A1 (en)	2002-12-19	Hepatitis b vaccine
HK1011930B (en)	2000-06-23	Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
HK1011930C (en)	2000-06-23	Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
HK1023499B (en)	2002-04-19	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a